Matthias Rottmann
Overview
Explore the profile of Matthias Rottmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
66
Citations
1850
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dupouy B, Karpstein T, Haberli C, Cal M, Rottmann M, Maser P, et al.
ChemMedChem
. 2024 Dec;
:e202400731.
PMID: 39676716
This study explores the synthesis and evaluation of novel 1,2,3-triazole-methyl-1,4-naphthoquinone hybrids, focusing on their electrochemical properties and antiparasitic efficacies against two human blood-dwelling parasites Plasmodium falciparum and Schistosoma mansoni. Using...
2.
Gal I, Demarta-Gatsi C, Fontinha D, Arez F, Wicha S, Rottmann M, et al.
ACS Infect Dis
. 2024 Dec;
11(1):69-79.
PMID: 39657997
New antimalarial combination therapies with novel modes of action are required to counter the emergence and spread of drug resistance against existing therapeutics. Here, we present a study to evaluate...
3.
Dupouy B, Cotos L, Binder A, Slavikova L, Rottmann M, Maser P, et al.
Chemistry
. 2024 Dec;
31(6):e202403691.
PMID: 39654502
The development of redox-sensitive molecular fluorescent probes for the detection of redox changes in Plasmodium falciparum-parasitized red blood cells remains of interest due to the limitations of current genetically encoded...
4.
Bravo P, Bizzarri L, Steinbrunn D, Lohse J, Hirsch A, Maser P, et al.
ACS Infect Dis
. 2024 Dec;
10(12):4073-4086.
PMID: 39631773
The limited understanding of the mechanism of action (MoA) of several antimalarials and the rise of drug resistance toward existing malaria therapies emphasizes the need for new strategies to uncover...
5.
Cesar-Rodo E, Dupouy B, Haberli C, Strub J, Williams D, Maser P, et al.
Molecules
. 2024 Nov;
29(22).
PMID: 39598657
Ψ-1,4-naphthoquinones (Ψ-NQ) are non-quinoid compounds in which aromaticity-found in 1,4-naphthoquinones-is broken by the introduction of an angular methyl at C-4a or -8a. This series was designed to act as prodrugs...
6.
Kumar A, Li Y, Dodean R, Roth A, Caridha D, Madejczyk M, et al.
ACS Infect Dis
. 2024 Nov;
10(12):4291-4300.
PMID: 39526703
Well-tolerated and novel antimalarials that can combat multiple stages of the parasite life cycle are desirable but challenging to discover and develop. Herein, we report results for natural product-inspired novel...
7.
Diamanti E, Steinbach A, de Carvalho L, Ropponen H, Lacour A, Hamid R, et al.
ACS Omega
. 2024 Nov;
9(44):44465-44473.
PMID: 39524657
The enzyme IspE in is considered an attractive drug target, as it is essential for parasite survival and is absent in the human proteome. Yet it still has not been...
8.
Dupouy B, Donzel M, Roignant M, Charital S, Keumoe R, Yamaryo-Botte Y, et al.
ACS Infect Dis
. 2024 Sep;
10(10):3553-3576.
PMID: 39327729
The apicoplast is an essential organelle for the viability of apicomplexan parasites or , which has been proposed as a suitable drug target for the development of new antiplasmodial drug-candidates....
9.
Willocx D, Bizzarri L, Alhayek A, Kannan D, Bravo P, Illarionov B, et al.
J Med Chem
. 2024 Sep;
67(19):17070-17086.
PMID: 39303294
The methyl-d-erythritol phosphate (MEP) pathway has emerged as an interesting target in the fight against antimicrobial resistance. The pathway is essential in many human pathogens, including (), but is absent...
10.
Maser P, Bernhard S, Brun R, Burri C, Gagneux S, Hetzel M, et al.
Chimia (Aarau)
. 2023 Dec;
77(9):593-602.
PMID: 38047835
Thanks to its expertise in clinical research, epidemiology, infectious diseases, microbiology, parasitology, public health, translational research and tropical medicine, coupled with deeply rooted partnerships with institutions in low- and middle-income...